| Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea D Sissoko, C Laouenan, E Folkesson, AB M’lebing, AH Beavogui, S Baize, ... PLoS medicine 13 (3), e1001967, 2016 | 567 | 2016 |
| Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life J Guedj, H Dahari, L Rong, ND Sansone, RE Nettles, SJ Cotler, ... Proceedings of the National Academy of Sciences 110 (10), 3991-3996, 2013 | 402 | 2013 |
| Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021 | 379 | 2021 |
| Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates P Maisonnasse, J Guedj, V Contreras, S Behillil, C Solas, R Marlin, ... Nature 585 (7826), 584-587, 2020 | 366 | 2020 |
| Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet Infectious Diseases 22 (2), 209-221, 2022 | 304 | 2022 |
| X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021 | 294 | 2021 |
| Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials V Madelain, THT Nguyen, A Olivo, X De Lamballerie, J Guedj, AM Taburet, ... Clinical pharmacokinetics 55 (8), 907-923, 2016 | 199 | 2016 |
| Timing of antiviral treatment initiation is critical to reduce SARS‐CoV‐2 viral load A Gonçalves, J Bertrand, R Ke, E Comets, X De Lamballerie, D Malvy, ... CPT: pharmacometrics & systems pharmacology 9 (9), 509-514, 2020 | 192 | 2020 |
| Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate RM Ribeiro, H Li, S Wang, MB Stoddard, GH Learn, BT Korber, ... Public Library of Science 8 (8), e1002881, 2012 | 180 | 2012 |
| Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort N Néant, G Lingas, Q Le Hingrat, J Ghosn, I Engelmann, Q Lepiller, ... Proceedings of the National Academy of Sciences 118 (8), e2017962118, 2021 | 179 | 2021 |
| Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted THT Nguyen, J Guedj, X Anglaret, C Laouénan, V Madelain, AM Taburet, ... PLoS neglected tropical diseases 11 (2), e0005389, 2017 | 167 | 2017 |
| Second‐phase hepatitis C virus RNA decline during telaprevir‐based therapy increases with drug effectiveness: implications for treatment duration J Guedj, AS Perelson Hepatology 53 (6), 1801-1808, 2011 | 129 | 2011 |
| Dose regimen of favipiravir for Ebola virus disease F Mentré, AM Taburet, J Guedj, X Anglaret, S Keïta, X de Lamballerie, ... The Lancet Infectious Diseases 15 (2), 150-151, 2015 | 128 | 2015 |
| Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques J Guedj, G Piorkowski, F Jacquot, V Madelain, THT Nguyen, A Rodallec, ... PLoS medicine 15 (3), e1002535, 2018 | 127 | 2018 |
| Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ... Nature communications 12 (1), 1735, 2021 | 124 | 2021 |
| Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study D Sissoko, S Duraffour, R Kerber, JS Kolie, AH Beavogui, AM Camara, ... The Lancet Global Health 5 (1), e80-e88, 2017 | 122 | 2017 |
| Maximum likelihood estimation in dynamical models of HIV J Guedj, R Thiébaut, D Commenges Biometrics 63 (4), 1198-1206, 2007 | 112 | 2007 |
| Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model L Rong, J Guedj, H Dahari, DJ Coffield Jr, M Levi, P Smith, AS Perelson PLoS computational biology 9 (3), e1002959, 2013 | 111 | 2013 |
| A perspective on modelling hepatitis C virus infection J Guedj, L Rong, H Dahari, AS Perelson Journal of viral hepatitis 17 (12), 825-833, 2010 | 108 | 2010 |
| Quantifying the relationship between SARS-CoV-2 viral load and infectiousness A Marc, M Kerioui, F Blanquart, J Bertrand, O Mitja, M Corbacho-Monné, ... Elife 10, e69302, 2021 | 106 | 2021 |
Alan S PerelsonSenior Fellow, Los Alamos National LaboratoryVerified email at lanl.gov
